PET Expert Panel Scans Alzheimer’s National Coverage Options
This article was originally published in The Gray Sheet
Executive Summary
CMS is considering limiting reimbursement of FDG PET for Alzheimer's disease diagnosis to specific clinical trial participants, according to Coverage & Analysis Group Director Steve Phurrough, MD
You may also be interested in...
PET Alzheimer’s Coverage Faces Uphill Battle Following AHRQ Report
A second 1AHRQ tech assessment finding insufficient evidence for PET in diagnosing Alzheimer's disease casts further doubt that CMS will reverse its national non-coverage policy for the indication
PET Alzheimer’s Coverage Faces Uphill Battle Following AHRQ Report
A second 1AHRQ tech assessment finding insufficient evidence for PET in diagnosing Alzheimer's disease casts further doubt that CMS will reverse its national non-coverage policy for the indication
CMS Requests Advice On Potential PET For Alzheimer’s Operational Issues
CMS is seeking public input on the types of minimal services that should be performed and documented before a PET scan is ordered to diagnose Alzheimer's disease